Objective To systematically review the dose-response relationship between cadmium exposure and the risk of stroke onset. Methods The PubMed, Web of Science, Cochrane Library, Embase, CNKI, VIP, WanFang Data, and CBM databases were electronically searched to collect studies related to objectives from inception to June 2024. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was then performed using Stata 15.1 software. Results There were 10 studies that involved 28 250 participants, and 7 of them were prospective cohort studies and 3 were case-control studies. Meta-analysis results showed that cadmium exposure significantly increased the risk of stroke (RR=1.39, 95%CI 1.20 to 1.59, P<0.01), blood cadmium exposure significantly increased the risk of stroke (RR=1.79, 95%CI 1.34 to 2.25, P<0.01), urinary cadmium exposure significantly increased the risk of stroke (RR=1.30, 95%CI 1.09 to 1.52, P<0.01). Blood cadmium exposure had a significantly nonlinear dose-response relationship associated with an increased risk of stroke (χ2=8.56, P<0.05). The risk of stroke increased by 15% with the blood cadmium exposure concentration of 0.8 μg/L (RR=1.15, 95%CI 0.98 to 1.36), and 51% with the blood cadmium exposure concentration of 1.2 μg/L (RR=1.51, 95%CI 1.14 to 2.01) than those without blood cadmium exposure. Urinary cadmium exposure had significantly linear dose-response relationship associated with an increased risk of stroke (χ2=2.47, P=0.12). The risk of stroke increased by 26% with the urinary cadmium exposure concentration of 0.8 μg/g (RR=1.26, 95%CI 1.20 to 1.31), and 31% with the urinary cadmium exposure concentration of 1.2 μg/g (RR=1.31, 95%CI 1.27 to 1.36) than those without urinary cadmium exposure. Conclusion Cadmium exposure increases the risk of stroke. There was a significant dose-response relationship between cadmium exposure and the risk of stroke.
Dose-response meta-analysis, an important tool in investigating the relationship between a certain exposure and risk of disease, has been increasingly applied. Traditionally, the dose-response meta-analysis was only modelled as linearity. However, since the proposal of more powerful function models, which contains both linear, quadratic, cubic or more higher order term within the regression model, the non-linearity model of dose-response relationship is also available. The packages suit for R are available now. In this article, we introduced how to conduct a dose-response meta-analysis using dosresmeta and mvmeta packages in R.
Objective
To investigate the effects of QUE on proliferation and DNA synthesis of cultured retinal pigment epithelium(RPE) cells with or without EGF.
Methods
With or without EGF, cultured RPE cells were treated with QUE by various concentrations(200,100,50,1mu;mol/L) and with QUE 200mu;mol/L at different times(24-168 hr), cells proliferation and DNA synthesis were evaluated by cell count method and the uptake of thymidine. The viability of cells was determined by trypanblue exclusion.
Results
The best concentration of QUE which inhibits proliferation and DNA synthesis of PRE cells was 200mu;mol/L. The significant inhibition effect of QUE occurred at 48hr, and the best inhibition of QUE occurred at 96hr. QUE had more powerful effect of antiproliferation on RPE cells, and the viability of RPE cells was over85%.
Conclusion
The results suggested that QUE could inhibit the proliferation of RPE cells in a dose-dependent and time-dependent manner, especially inhibit the proliferation induced by EGF stimulating. QUE had no cyto-toxic effect on RPE cells cultured in vitro.
(Chin J Ocul Fundus Dis,1999,15:27-29)
Does-response meta-analysis, which has being developed for more than 30 years, is a type of regression function and can be both linear and non-linear model. It plays an important role in investigating the relationship between dependent and independent variable. With its special advantages, dose-response meta-analysis has been widely used in evidence-based practice and decision. Currently there are several models can be used to perform dose-response metaanalysis with various advantages and disadvantages. It is vital to choose best model to perform dose-response metaanalysis in evidence-based practice. In this paper, we briefly introduce and summarize the methodology of dose-response meta-analysis.
Objective To assess the radiation dose and image quality with low-dose multi-detector row CT urography （CTU） for the evaluation of children patients with ureteropelvic junction stenosis （UJS）. Methods In this prospective study， 30 children patients with UJS underwent CTU were classified half-randomly through exam numbers into 3 groups （115 mA， 100 mA， and 75 mA）. Consecutive acquisitions including CT dose index weighted （CTDIw） and dose long product （DLP） were obtained in each patient and compared for each group. Three experienced chest radio-logists were unaware of the CT technique reviewed CT images for overall image quality using a 3-grade scale （excellent， good， and worst）. The data were analyzed using a parametric analysis of variance test and Wilcoxon’s signed rank test. Results The CTDIws of 115 mA group， 100 mA group， and 75 mA group were （7.63±0.83） mGy， （6.29±0.51） mGy， and （4.72±0.18） mGy， respectively， the difference was significant among three groups （F=36.445， P=0.000）. The mean CTDIw reduction was 38.2% in the 75 mA group as compared with 115 mA group （P＜0.001）. The DLPs of 115 mA group， 100 mA group， and 75 mA group were （173.89±29.88） mGy?cm， （145.96±26.21） mGy?cm， and （102.78±12.72） mGy?cm， respectively， the difference was significant among three groups （F=13.955， P=0.000）. The mean radiation dose reduction was 40.9% （75 mA group versus 115 mA group， P＜0.001）. The assessment of image quality was no significant difference with the same protocol and post-processing technique （Wilcoxon’s signed rank test， P＞0.05）. There was a good agreement for image quality scoring among the three reviewers （Kappa=0.736）. Conclusion Low-dose multi-detector row CTU should be considered as a promising technique for the evaluation of children patients with UJS because it could decrease radiation dose and obtain acceptable image quality.
As a valid method in systematic review, dose-response meta-analysis is widely used in investigating the relationship between independent variable and dependent variable, and which usually based on observational studies. With large sample size, observational studies can provide a reasonable amount of statistical power for meta-analysis. However, due to the design defects of observational studies, they tend to introduce many kinds of biases, which may influence the final results that make them deviation from the truth. Given the dead zone of methodology, there is no any bias adjusting method in dose-response meta-analysis. In this article, we will introduce some bias adjusting methods from other observational-study-based meta-analysis and make them suit for dose-response meta-analysis, and then compare the advantages and disadvantages of these methods.
Objective According to health technology assessment (HTA) methodology, to assess the efficacy and safety of different doses of metoprolol in the treatment of atrial fibrillation (AF). Methods Based on the principles of HTA, we searched some important medical databases including MEDLINE, EMBASE, The Cochrane Library and CMCC, as well as several national special heart disease databases and side effect centers. We selected eligible studies based on the inclusion and exclusion criteria and critically assessed their quality. Results Intravenous metoprolol 10 mg - 15 mg could control rapid ventricular rate in patients with chronic AF. On either rest or exercise, oral metoprolol 150 mg/d had a better control of rapid ventricular rate than 50 mg/d in patients with chronic AF. For preventing postoperative AF (POAF), the intravenous metoprolol 20 mg group and the 30 mg group could decrease the incidence of POAF compared to the 10 mg group. Oral metoprolol 150 mg/d was more effective than 100 mg/d in preventing POAF. In addition, intravenous metoprolol therapy was well-tolerated and more effective than oral metoprolol therapy in preventing atrial fibrillation after cardiac surgery. Results from several national side effect centers demonstrated that the incidence of adverse reactions associated with metoprolol was low. Conclusion Present evidence showed that high dose of metoprolol was superior to low dose in treating AF, however, the evidence available is insufficient. It is suggested that adequate evidence through further studies are needed. The safety profile of different doses of metoprolol is similar.
In evidence-based practice and decision, dose-response meta-analysis has been concerned by many scholars. It can provide unique dose-response relationship between exposure and disease, with a high grade of evidence among observational-study based meta-analysis. Thus, it is important to clearly understand this type of meta-analysis on software implementations. Currently, there are different software for dose-response meta-analysis with various characteristics. In this paper, we will focus on how to conduct dose-response meta-analysis by Stata, R and SAS software, which including a brief introduction, the process of calculation, the graph drawing, the generalization, and some examples of the processes.
ObjectiveTo systematically evaluate the dose-response relationship between coffee consumption and liver cancer risk. MethodsThe PubMed, Web of Science, Cochrane Library, EMbase, CNKI, VIP, WanFang Data, and CBM databases were searched from inception to December 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was then performed by using Stata 17.0 software. ResultsFifteen studies (11 cohort studies and 4 case-control studies) involving 557 259 participants were included. The results of meta-analysis showed that coffee consumption was significantly negatively associated with the risk of liver cancer (RR=0.39, 95%CI 0.27 to 0.57, P<0.01). The dose-response meta-analysis showed a non-linear dose-response relationship between coffee consumption and the risk of liver cancer (P<0.01). Compared with people who did not drink coffee, people who drank 1 cup of coffee a day had a 25% lower risk of liver cancer (RR=0.75, 95%CI 0.67 to 0.83), and people who drank 2 cups of coffee a day had a 38% lower risk of liver cancer (RR=0.62, 95%CI 0.56 to 0.70). The risk of liver cancer decreased by 45% (RR=0.55, 95%CI 0.48 to 0.62) for 3 cups of coffee and by 51% (RR=0.49, 95%CI 0.43 to 0.56) for 4 cups of coffee. ConclusionCurrent evidence suggests that there is a nonlinear dose-response relationship between coffee consumption and the risk of liver cancer. These results indicate that habitual coffee consumption is a protective factor for liver cancer. Due to the limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusion.
Objective To assess the rationale for including rifampicin150/isoniazid75/ethambuto/275mg fixed dose, combination oral tablets/3-FDC R150H75E275/ in the WHO Model List of Essential Medicines (WHO EML) for treatment of category II tuberculosis (TB II) and to provide evidence for the updating of national guidelines. Methods We searched Chinese Biomedical Database (CBM, 1978 to 2006), The Cochrane Library, Issue 4, 2006, the Database of Abstracts of Reviews of Effects (1994 to 2006, the Centre for Reviews and Dissemination website), MEDLINE (1950 to 2006), EMBASE (1974 to 2006), BIOSIS Previews (1997 to 2006), websites for grey literature and the references of studies. We applied inclusion and exclusion criteria in assessing the studies we found and eligible studies were graded following an assessment of their quality. Results Thirty-six randomized controlled trials, 4 controlled clinical trials, 11 descriptive studies and 5 WHO/national guidelines were included. Rifampicin (R), isoniazid (H) and ethambutol (E) were used in the ccontinuation phase (CP) of TB II in guidelines of WHO and high tuberculosis (TB) burden countries, but the course of treatment and dosage regimens varied. R, H and E were also widely used in conditions of pulmonary tuberculosis (PTB), extrapulmonary tuberculosis (EPTB) and pulmonary diseases caused by nontuberculous mycobacteria (NTM).Conclusions It is recommended that FDC RHE be included in WHO EML for the treatment of TB II.The suggested dosage ratio of RHE is 1:1:2, which needs to be adjusted based on more solid clinical evidence. High quality clinical studies and systematic reviews on the effectiveness, safety, economics and applicability of WHO and national guidelines and their outcomes in high TB burden countries are needed to guide their updating, promote rational resource allocation and improve cost effectiveness. Alternative drugs or drug combinations with good profile of effectiveness, safety, economics, and applicability for the prevention and treatment of drug-resistant tuberculosis are also needed to be developed.
